Talimogene laherparepvec

Pharmacologic Class

  • Oncolytic viral therapy (genetically modified herpes simplex virus type-1, HSV-1).
  • Intralesional immunotherapy for melanoma.

Indications

  • FDA-approved:
    • Local treatment of unresectable cutaneous, subcutaneous, and nodal melanoma lesions in patients with recurrent melanoma after initial surgery.
  • Not indicated for visceral disease (lung, bone, liver, brain mets).

Mechanism of Action

  • Direct oncolysis: HSV-1 selectively replicates in tumor cells, causing lysis.
  • Immunostimulation: Encodes GM-CSF, enhancing dendritic cell activation and T-cell–mediated anti-tumor immune response.
  • Creates local and systemic immune activation (“abscopal effect”).

Dosing & Administration

  • Route: Intralesional injection.
  • Schedule:
    • First dose: ≤4 mL of 10^6 PFU/mL.
    • Second dose (3 weeks later): ≤4 mL of 10^8 PFU/mL.
    • Then: every 2 weeks, ≤4 mL of 10^8 PFU/mL, until no injectable lesions remain, disease progression, or unacceptable toxicity.
  • Dose is based on lesion size, not patient weight.

Adverse Effects

  • Very common:
    • Fatigue, chills, fever, flu-like symptoms.
    • Injection site pain, erythema, cellulitis-like reactions.
    • Nausea, vomiting.
  • Serious:
    • Disseminated herpetic infection (risk higher in immunocompromised).
    • Immune-mediated adverse events (rare).
    • Secondary bacterial infections at injection site.

Contraindications

  • Immunocompromised patients (risk of disseminated herpes).
  • Pregnant women (HSV transmission risk).
  • Active herpetic infection without appropriate antiviral coverage.

Monitoring

  • Lesion assessment: Every cycle to guide continued injection.
  • Immune status: Avoid in severe immunosuppression.
  • Signs of herpetic infection: Especially in healthcare workers and close contacts.

Handling Precautions

  • Biosafety: Standard precautions for live virus.
  • Avoid contact with lesions, body fluids, dressings.
  • Cover injected lesions with occlusive dressings.
  • Caregivers should use gloves when handling dressings.

Clinical Pearls

  • Responses can be slow; patients may initially appear to progress before regression (“pseudo-progression”).
  • Works best in patients with limited, injectable, non-visceral melanoma disease.
  • Has been studied in combination with checkpoint inhibitors (e.g., ipilimumab, pembrolizumab) → shows improved response rates.
  • Not systemically immunosuppressive, unlike many traditional cancer therapies.
Links